Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: The story says the federal government is paying about $2,250 per patient for a standard 5-day treatment course. It also notes that the approved alternative treatments are less expensive. The story points out that the benefits of peramivir have yet to be proven and that it is being offered only because some patients are not helped by approved drugs or are they are so sick they need a drug that can be given intravenously. The approved antiviral drugs are currently available only in pill or inhaled form. The story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs. These side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers: "The most common side effects of PERAMIVIR are: diarrhea nausea vomiting white blood cell count decreased These side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time. Other medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. These side effects include: Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior. Allergic reaction or severe rash Not a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot." Patient fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf Provider fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf The story points out more than once that peramivir is still being tested and that questions remain about its potential effectiveness. The story points out that the experimental drug is being offered only to patients who are already in the hospital and aren't being helped by approved drugs. The story did not point out that one of the supporters of faster and broader access to peramivir, Dr. Richard Whitley, has long been a booster of the drug, which is being commercially developed by a spin-off of the University of Alabama department he works in. See Whitley comments in a 2005 article promoting the potential of peramivir: http://main.uab.edu/show.asp?durki=87834 Here we also point out that the story profiled only one patient and includes a quote from the patient's father crediting peramivir with saving his daughter's life. The story does not give any examples of similar patients who either survived after getting approved drugs or who received peramivir and yet did not survive. Despite the clear caveats in the story, the reliance on only a single anecdote may give readers a skewed sense of the benefits of the unapproved drug. The story makes clear that the approved antiviral flu drugs are Tamiflu and Relenza. The story makes very clear that peramivir is experimental and is being offered only because some patients cannot take or aren't helped by approved antiviral drugs. The story is quite clear that peramivir is still being tested. The story does not appear to rely on a news release.
[A]: New Drug for H1N1 Flu Offers Hope

[Q]: In a report issued Thursday, the U.N. health agency said the number of measles cases from January to June this year is double the number reported for the same period in 2018. Measles is among the world's most infectious diseases and is spread mostly by coughing, sneezing and close personal contact. Although numerous European countries have introduced stronger vaccination policies, stubborn pockets of vaccine refusal have fueled epidemics across the continent. Last month, the German government proposed making measles immunization mandatory for children and employees at kindergartens and schools; there have been more than 400 cases of measles in Germany this year. With more than 84,000 cases, Ukraine accounted for the vast majority of measles in Europe, followed by Kazakhstan and Georgia. In February, Ukraine's health ministry said eight people had died of measles. An expert WHO committee said four countries Albania, the Czech Republic, Greece and the U.K. have now lost their status as having eliminated measles. Measles is preventable with two doses of the vaccine, but there is no effective treatment once people are infected. "If high immunization coverage is not achieved and sustained in every community, both children and adults will suffer unnecessarily and some will tragically die," said Dr. Guenter Pfaff, chair of a WHO expert committee on measles in Europe. In some developed countries, measles vaccination rates dropped sharply following the publication of a flawed study in the late 1990s that linked the combined measles, mumps and rubella vaccine to autism. Health officials have struggled to debunk misperceptions about the vaccine's safety ever since. "Misinformation about vaccines is as contagious and dangerous as the diseases it helps to spread," WHO Director-General Tedros Adhanom Ghebreyesus in a statement this week. In 2017, WHO estimated about 110,000 people died from measles worldwide, mostly children under 5-years-old.
[A]: 'Dramatic resurgence' of measles seen in Europe, WHO reports.

[Q]: A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen's version of AbbVie's Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug. For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen's drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients. But it could take years for those savings to arrive. Evercore ISI analyst Mark Schoenebaum says the earliest Amgen could launch its product would be March 2017, though that would risk infringing patents which Abbvie says protect its drug until at least 2022. Wall Street analysts expect the patent issue to be fought in court, and then for Amgen's drug to launch sometime between 2018 and 2022. First approved in 2002, Humira has long been among the most profitable drugs in the world. It accounted for 60 percent of Abbvie's total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is approved for multiple uses, including rheumatoid arthritis, Crohn's disease and psoriasis. Thousand Oaks, Calif-based Amgen is seeking FDA approval to market its version, known only as ABP 501, for seven diseases. Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors' drugs. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales. The FDA only approved the first lower-cost biotech drug last March, a Novartis version of the Amgen drug Neupogen. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson's Remicade, but it is not yet for sale. Questions remain about just how much savings U.S. biosimilars will deliver. Novartis' Zarxio sells for 15 percent less than the original Neupogen. Experts predict biosimilar discounts of 15 percent to 30 percent in the U.S. In Europe, where governments regulate prices, discounts are higher. Development of lower-cost anti-inflammatory drugs like Humira is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. On Wednesday, the same panel of FDA advisers will review a Novartis version of Enbrel, which is marketed by Amgen.
[A]:
Lower-cost biotech drug gets thumbs up from FDA panel.